ASML Q3 Beats on Margin and Cash, but Valuation and Execution Risks Persist

What happened

ASML's Q3 2026 results reinforced the strength of AI-driven demand for its lithography tools, with revenue up 55% year-over-year to €11.7 billion and gross margin expanding to 57.5%, above the guided range. Free cash flow surged over 4,500% year-over-year, reflecting improved working capital and strong collections, which addresses earlier concerns about cash conversion. Management raised the bottom end of full-year revenue guidance to €44 billion, keeping the top at €45 billion, signaling confidence in continued order momentum. However, the quarter does not directly resolve the two key risks from the previous WAIT thesis: the ability to expand 2027 capacity by 30% and the impact of potential China export restrictions. While the results are strong, they were largely expected given the raised guidance in Q2, and the stock's high valuation (59x P/E) limits the margin of safety for new buyers.

Implication

The Q3 beat is reassuring but does not change the fundamental setup for ASML, which still requires flawless execution on capacity expansion and navigation of geopolitical restrictions. The raised revenue guidance is a modest positive, but it remains within the prior range and does not suggest a step-change in demand beyond what was already communicated. The stock's valuation at ~59x P/E and ~47x EV/EBITDA leaves little room for error, and any slippage in capacity ramp or China mix could trigger a de-rating. For existing holders, the strong cash flow and margin performance justify patience, but new positions should wait for a pullback toward the attractive entry zone around $1,550 or clearer evidence that 2027 capacity will be delivered on time. Key monitoring points over the next quarter include China's revenue contribution, any changes to capacity plans, and whether quarterly sales can exceed €12 billion to trigger an upgrade.

Thesis delta

The Q3 results confirm the AI demand thesis and improve the margin and cash conversion profile, but they do not address the core execution risks (2027 capacity expansion and China exposure) that led to the WAIT rating. The thesis remains largely unchanged, with a slight positive tilt from stronger-than-expected profitability. An upgrade to BUY would require evidence that capacity plans are on track and that China risk is manageable, or a more attractive valuation.